BR0215303A - Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol - Google Patents

Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol

Info

Publication number
BR0215303A
BR0215303A BR0215303-3A BR0215303A BR0215303A BR 0215303 A BR0215303 A BR 0215303A BR 0215303 A BR0215303 A BR 0215303A BR 0215303 A BR0215303 A BR 0215303A
Authority
BR
Brazil
Prior art keywords
water
formulations
pharmaceutical formulations
propofol
soluble
Prior art date
Application number
BR0215303-3A
Other languages
English (en)
Inventor
Tracey L Rogers
Jeffey A Williamson
Christopher A Rhodes
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of BR0215303A publication Critical patent/BR0215303A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS DE BASE AQUOSA DE PRó-DROGAS SOLúVEIS EM áGUA DE PROPOFOL". A presente invenção está direcionada a formulações de base aquosa de pró-drogas solúveis em água de propofol. As formulações compreendem em um veículo aquoso uma quantidade eficaz da pró-droga solúvel em água de propofol e uma quantidade eficaz de um anti-oxidante. Em uma modalidade, a formulação também contém um modificador de tonicidade. As formulações são particularmente úteis como injeções intravenosas. As formulações preferivelmente são tamponadas em um pH adequado para minimizar a degradação da pró-droga durante o armazenamento. Vantajosamente, as formulações podem ser preparadas sem o uso de tensoativos e co-solventes danosos, e são estáveis em temperatura ambiente durante períodos prolongados de tempo.
BR0215303-3A 2001-12-28 2002-12-26 Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol BR0215303A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34275501P 2001-12-28 2001-12-28
PCT/US2002/041468 WO2003057153A2 (en) 2001-12-28 2002-12-26 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol

Publications (1)

Publication Number Publication Date
BR0215303A true BR0215303A (pt) 2005-04-05

Family

ID=23343142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215303-3A BR0215303A (pt) 2001-12-28 2002-12-26 Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol

Country Status (22)

Country Link
US (1) US20050042280A1 (pt)
EP (1) EP1458355B1 (pt)
JP (2) JP2005517679A (pt)
KR (2) KR20100112632A (pt)
CN (1) CN1329036C (pt)
AT (1) ATE430571T1 (pt)
AU (1) AU2002364238B2 (pt)
BR (1) BR0215303A (pt)
CA (1) CA2470500C (pt)
DE (1) DE60232271D1 (pt)
ES (1) ES2325918T3 (pt)
HK (1) HK1069976A1 (pt)
HU (1) HU229293B1 (pt)
IL (3) IL162692A0 (pt)
MX (1) MXPA04006325A (pt)
NO (1) NO334424B1 (pt)
NZ (1) NZ533536A (pt)
PL (1) PL205271B1 (pt)
RU (1) RU2316317C2 (pt)
UA (1) UA76802C2 (pt)
WO (1) WO2003057153A2 (pt)
ZA (1) ZA200404616B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543166A1 (en) 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. Ph sensitive prodrugs of 2,6-diisopropylphenol
US7589239B2 (en) 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
EP2068630A4 (en) * 2006-10-05 2010-12-29 Eisai Inc AQUEOUS PHARMACEUTICAL FORMULATIONS OF WATER SOLUBLE PRODRUGS OF PROPOFOL
MX2009012124A (es) 2007-05-09 2010-02-18 Pharmacofore Inc Compuestos terapeuticos estereoisomeros de propofol.
JP2010526827A (ja) 2007-05-09 2010-08-05 ファーマコフォア，インク． 治療用化合物
US20090098209A1 (en) * 2007-10-15 2009-04-16 University Of Kansas Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
GB0905834D0 (en) 2009-04-03 2009-05-20 Seps Pharma Nv Phosphonyl-containing phenolic derivatives useful as medicaments
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
CN110063947A (zh) * 2018-01-24 2019-07-30 四川海思科制药有限公司 苯酚衍生物用于制备***物中的用途
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
CN114129578A (zh) * 2021-09-28 2022-03-04 瑞普（天津）生物药业有限公司 甲磷丙泊酚钠在制备宠物麻醉、镇静药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2829151A (en) * 1952-11-03 1958-04-01 Dow Chemical Co Chlorotoloxy-ethyl phosphates
US3271314A (en) * 1958-12-04 1966-09-06 Ethyl Corp 2, 6-diisopropylphenol
GB1146173A (en) * 1966-06-18 1969-03-19 Geigy Uk Ltd Production of triaryl phosphates
US3723578A (en) * 1970-10-13 1973-03-27 Gaf Corp Phosphate esters of ethers of thiol substituted phenols
US4171272A (en) * 1977-12-02 1979-10-16 Fmc Corporation Turbine lubricant
FR2601259B1 (fr) * 1986-07-11 1990-06-22 Rhone Poulenc Chimie Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives.
MY103951A (en) * 1988-01-12 1993-10-30 Kao Corp Detergent composition
US5091211A (en) * 1989-08-17 1992-02-25 Lord Corporation Coating method utilizing phosphoric acid esters
US5110503A (en) * 1990-05-15 1992-05-05 Elliot Cohen Demulsifying
JP2869186B2 (ja) * 1990-10-17 1999-03-10 株式会社トーメン 植物における生物活性剤の吸収移行を促進する方法及び組成物
US5908860A (en) * 1992-12-11 1999-06-01 Smithkline Beecham Plc, Bicyclic compounds with pharmaceutical activity
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
KR960008645B1 (ko) * 1993-09-08 1996-06-28 동국제약 주식회사 오르토-이소프로필화 페놀 유도체의 제조방법
US5731355A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
IT1270093B (it) * 1994-09-28 1997-04-28 Zambon Spa Processo per la purificazione di 2,6-diisopropilfenolo
US5804682A (en) * 1995-11-29 1998-09-08 Henkel Corporation Aqueous dispersions of polyamides
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US5723538A (en) * 1996-06-14 1998-03-03 Henkel Corporation Aqueous dispersions of polyamides
US5746973A (en) * 1996-07-10 1998-05-05 Naraghi; Ali Method for reducing odorant depletion
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
EA004708B1 (ru) * 2000-02-04 2004-06-24 Эли Лилли Энд Компани Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
MXPA02011531A (es) * 2000-05-25 2003-04-25 Astrazeneca Ab Beneficio de superviviencia.
IN187686B (pt) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
US20050042280A1 (en) 2005-02-24
EP1458355A2 (en) 2004-09-22
JP2005517679A (ja) 2005-06-16
JP2010235622A (ja) 2010-10-21
ES2325918T3 (es) 2009-09-24
AU2002364238B2 (en) 2007-01-18
DE60232271D1 (de) 2009-06-18
HU229293B1 (hu) 2013-10-28
HK1069976A1 (en) 2005-06-10
AU2002364238A1 (en) 2003-07-24
EP1458355A4 (en) 2005-04-20
PL205271B1 (pl) 2010-03-31
HUP0500439A2 (hu) 2005-08-29
EP1458355B1 (en) 2009-05-06
NO334424B1 (no) 2014-03-03
WO2003057153A2 (en) 2003-07-17
ATE430571T1 (de) 2009-05-15
CA2470500C (en) 2012-05-15
RU2316317C2 (ru) 2008-02-10
KR20040080444A (ko) 2004-09-18
MXPA04006325A (es) 2005-03-31
WO2003057153A3 (en) 2004-01-29
CN1329036C (zh) 2007-08-01
ZA200404616B (en) 2005-10-26
UA76802C2 (uk) 2006-09-15
PL372324A1 (en) 2005-07-11
RU2004119056A (ru) 2005-04-20
IL208697A0 (en) 2010-12-30
IL162692A0 (en) 2005-11-20
CA2470500A1 (en) 2003-07-17
CN1607938A (zh) 2005-04-20
IL162692A (en) 2011-03-31
KR20100112632A (ko) 2010-10-19
NO20042459L (no) 2004-08-25
NZ533536A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
ES2081936T3 (es) Composiciones anfoteras y formas polimericas de alfa-hidroxiacidos, y su uso terapeutico.
EA200200880A1 (ru) Агротехническая композиция
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
DE60222273D1 (de) Befeuchtungsmittel und dieses enthaltende kosmetika und topische präparate
ES2194679T3 (es) Composiciones cosmeticas que contienen creatina, carnitina y/o acido piruvico.
AR085989A2 (es) Composiciones endoparasiticidas y proceso para su preparacion
MXPA05012753A (es) Composiciones cosmeticas estables que comprenden un agente autobronceador.
PT1589949E (pt) Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
WO2008045189A3 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
PT769951E (pt) Composicao de oxitetraciclina de longa accao
ATE245968T1 (de) Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung
WO2006059221A3 (en) Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents
CO5261624A1 (es) Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
BR0108727A (pt) Composição micelar para o tratamento de doenças parasìticas em animais, e, uso de uma composição
EP1314726A4 (en) NEW ESTER OR AMID DERIVATIVES
PT1299114E (pt) Composicao farmaceutica de diclofenac com base em vitamina e, papina e hialuronidase
HRPK20040924B3 (en) Preparation based on curcumae longae rhizomae roots
ECSP993220A (es) Derivados de 3,3- biarilpiperidina y 2,2 - biarilmorfolina
TH57759B (th) ยาเม็ดที่มีการปลดปล่อยในทันที

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MGI GP INC. (US)

Free format text: ALTERADO DE: GUILFORD PHARMACEUTICALS INC.

B25G Requested change of headquarter approved

Owner name: MGI GP INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060149192/RJ DE 27/09/2006.

B25A Requested transfer of rights approved

Owner name: EISAI CORPORATION OF NORTH AMERICA (US)

Free format text: TRANSFERIDO DE: MGI GP INC.

B25A Requested transfer of rights approved

Owner name: EISAI INC. (US)

Free format text: TRANSFERIDO DE: EISAI CORPORATION OF NORTH AMERICA

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 9/00, A01N 57/00, A01N 31/08, A61P 23/00, A61P 25/20

Ipc: A61K 9/00 (2011.01), A01N 57/00 (2011.01), A01N 31

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]